Samsung Biologics announces investment plan to build future of biopharma
Singapore, Nov. 19 -- Samsung Biologics has officially begun construction of its Plant 4 in Incheon, South Korea. Dubbed the "Super Plant," the new, multi-story 238,000-square-meter construction will be the world's largest biopharmaceutical manufacturing facility of its kind boasting 256,000 liters total manufacturing capacity.
In a joint event with the Korean government and the Incheon City, Samsung Biologics showcased a virtual groundbreaking ceremony in light of COVID-19 protocols and announced an investment plan to build the "Future of Biopharma."
Upon completion of Plant 4, Samsung Biologics is expected to be accountable for a third of the total global bio-CMO manufacturing capacity, offering a combined sum of 620,000 liters from a...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.